Cardiovascular risk factors in acromegaly before and after normalization of serum IGF-I levels with the GH antagonist pegvisomant - Sesmilo, G; Fairfield, W P; Katznelson, L; Pulaski, K; Freda, P U; Bonert, V; Dimaraki, E; Stavrou, S; Vance, M L; Hayden, D; Klibanski, A (J Clin Endocrinol Metab, 2002)